ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1842

Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients

Yifang Mei, Xiaoping Sun, Yuxia Shao, Huanhuan Zhan and Zhiyi Zhang, Department of Rheumatology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Systemic lupus erythematosus (SLE) is a kind of chronic and autoimmune disease with variable multi-system involvement of unknown causes, which is characterized by periods of relapsing-remitting course. Inflammation and vascular abnormalities are the main pathological changes. Part of the SLE patients may present with pulmonary artery hypertension (PAH), which can seriously affect the quality of life and eventually lead to death. The etiology and pathogenesis of PAH is affected by many factors which have not yet been fully elucidated. Till now, there is no highly sensitive and specific biomarker for early diagnosis and prognosis for SLE patients with PAH. The aim of this study is to investigate the plasma level of pentraxin 3 (PTX3) and its clinical significance as a potential biomarker in SLE patients.

Methods:  1) In this study, 46 patients with SLE were enrolled. The diagnostic criteria for SLE were based on the American College of Rheumatology (ACR) revised criteria in 1997 or ACR revised SLE classification standards in 2009. All subjects retained serum and plasma samples, and recorded contemporary clinical manifestations and laboratory data, including duration, clinical symptoms and signs, blood-urine- defecate-test, liver and kidney function, blood lipids, erythrocyte sedimentation rate, C-reactive protein, complement series, antinuclear antibodies (ANAs), anti-ds-DNA antibodies, antiphospholipid antibodies and immunoglobulin, SLEDAI and other data. SLE patients were divided into two groups, activity group and no activity group according to the SLEDAI; further, the activity group was divided into three subgroups, mild, moderate and severe group; all patients were measured by the UCG, PASP≥40mmHg was determined SLE-PAH (add up to 26 cases), while PASP <25 mmHg was the SLE-NPAH (20 cases). 2) 21 healthy subjects were selected as controls. All subjects were collected serum and plasma, stored at -80℃. 3) Enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay (ECLIA) were used to detect plasma PTX3 level and serum NT-proBNP level, respectively.

Results:  1) The levels of PTX3 and NT-proBNP of SLE group were significantly higher than healthy control group (P=0.007 and 0.013, respectively). 2) Among SLE patients, PTX3 and NT-proBNP levels increased significantly of SLE-PAH group than those of SLE-NPAH (P=0.001 and 0.022, respectively). 3) The expression of PTX3 in activity group was higher than non-active group (P=0.029). There was no significant difference among mild, moderate and severe activity SLE group in the expression of PTX3 (P=0.14). 4) There was no significant correlation between the levels of PTX3 and NT-proBNP in patients with SLE-PAH (r=0.098, P=0.655). 5) In SLE-PAH group, the expression of PTX3 was positively correlated with SLEDAI scores (r=0.350, P=0.017), while negatively correlated with serum albumin (r=-0.327, P=0.018) ;PTX3 has no correlation with CRP (r=0.097, P=0.651), but was positively correlated with CRP by adjusting age and sex (r=0.178, P<0.001). 6) Multiple linear regression analysis showed that SLEDAI sores were independent predictors of PTX3 level. 7) Receiver operating characteristic (ROC) curve demonstrated the plasma PTX3 level more accurately than NT-proBNP in distinguishing SLE-PAH from SLE-NPAH .

Conclusion:  The circulating levels of PTX3 in SLE-PAH were significantly higher, and positively correlated with CRP level, indicating that PTX3 may be involved in SLE-PAH development. PTX3 may be a sensitive biomarker for SLE-PAH diagnosis.


Disclosure: Y. Mei, None; X. Sun, None; Y. Shao, None; H. Zhan, None; Z. Zhang, None.

To cite this abstract in AMA style:

Mei Y, Sun X, Shao Y, Zhan H, Zhang Z. Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pentraxin-3-level-positively-correlated-with-pulmonary-arterial-hypertension-in-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pentraxin-3-level-positively-correlated-with-pulmonary-arterial-hypertension-in-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology